Redo Transcatheter Aortic Valve Replacement Safe, Effective

MONDAY, Sept. 11, 2023 (HealthDay News) -- Redo transcatheter aortic valve replacement (TAVR) procedures are as safe and effective as native TAVR in select patients, according to a study published online Aug. 31 in The Lancet.
Raj R. Makkar, M.D., from Cedars-Sinai Medical Center in Los Angeles, and colleagues assessed the safety and efficacy of redo TAVR in a national registry. The analysis included all consecutive patients in the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry (Nov. 9, 2011, to Dec. 30, 2022) who underwent TAVR with balloon-expandable valves in either failed transcatheter heart valves (redo TAVR; 1,320 patients) or native aortic valves (native TAVR; 349,271 patients).
The researchers found that the rates of procedural complications of redo TAVR were low (coronary compression or obstruction: 0.3 percent; intraprocedural death: 0.6 percent; conversion to open heart surgery: 0.5 percent) and overall similar to native TAVR. For death at 30 days (4.7 versus 4.0 percent) or one year (17.5 versus 19.0 percent) and stroke at 30 days (2.0 versus 1.9 percent) or one year (3.2 versus 3.5 percent), there were no significant differences between redo-TAVR and native-TAVR populations, respectively. At one year, redo TAVR reduced aortic valve gradients, although they were higher in the redo-TAVR group versus the native-TAVR group (15 versus 12 mm Hg). Rates of moderate or severe aortic regurgitation did not differ significantly between the redo-TAVR and native-TAVR groups at one year (1.8 versus 3.3 percent). Timing of redo TAVR (before or after one year of index TAVR) and index transcatheter valve type (balloon-expandable or non-balloon-expandable) did not significantly affect death or stroke after redo TAVR.
"Redo-TAVR with balloon-expandable valves might be a reasonable treatment for failed TAVR in selected patients," the authors write.
Edwards Lifesciences funded the study.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Related Posts
Prednisone Does Not Improve In Vitro Fertilization Outcomes
FRIDAY, May 5, 2023 (HealthDay News) -- Among patients with recurrent...
Una terapia experimental podría ser una nueva herramienta contra el cáncer de páncreas
JUEVES, 2 de junio de 2022 (HealthDay News) -- En lo que podría resultar un...
EE. UU. crea una base de datos de 300 millones de dólares para la investigación sobre el Alzheimer
MIÉRCOLES, 5 de abril de 2023 (HealthDay News) -- Una nueva base de datos...
Eating Lots of ‘Ultra-Processed’ Foods Could Harm Your Brain
TUESDAY, Dec. 6, 2022 (HealthDay News) -- Chips, pizza, cookies: Delicious, but...
